The state of Kentucky currently has 12 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including Louisville, Lexington, Owensboro and Paducah.
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: University of Kentucky Chandler Medical Center, Lexington, Kentucky
Conditions: Episodic Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Qualmedica Research, LLC, Bowling Green, Kentucky +2 locations
Conditions: Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Qualmedica Research, LLC, Bowling Green, Kentucky +2 locations
Conditions: Migraine
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2024
Locations: University of Kentucky Chandler Medical Center, Lexington, Kentucky
Conditions: Chronic Migraine
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Kentucky Neuroscience Institute Child Neurology-- "Patients Seen", Lexington, Kentucky +2 locations
Conditions: Pediatric Migraine
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/10/2024
Locations: University of Kentucky HealthCare (UKHC) Kentucky Clinic, Lexington, Kentucky
Conditions: Chronic Migraine in Children
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: University of Kentucky Hospital, Lexington, Kentucky
Conditions: Acute Treatment of Migraine
Register for Updates
Responding With Evidence and Access for Childhood Headaches
NCT05889624
Recruiting
This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will b... Read More
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
05/13/2024
Locations: University of Louisville Health/Norton, Louisville, Kentucky
Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110
Recruiting
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/07/2024
Locations: Teva Investigational Site 14327, Louisville, Kentucky
Conditions: Migraine
Register for Updates
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/03/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Migraine
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
NCT04464707
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical out... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/28/2024
Locations: Teva Investigational Site 14327, Louisville, Kentucky
Conditions: Migraine
Register for Updates
Auricular Acupuncture vs SOC in Migraine HA
NCT02681211
Recruiting
Patients with migraine headache will be offered the opportunity to participate in this randomized study evaluating auricular acupuncture versus standard treatment for migraine headaches for patients in the pediatric emergency department (ED).
Gender:
All
Ages:
Between 8 years and 18 years
Trial Updated:
10/05/2023
Locations: Norton Children's Hospital, Louisville, Kentucky +1 locations
Conditions: Migraine Headache
Register for Updates